News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Discover Latest #Euro News, Articles and Videos with Contenting
1. "EU Proposes New Rules on Digital Tax to Make Tech Giants Pay Their Share" - This article from Reuters discusses how the European Union's executive branch proposed new rules for digital taxation to ensure tech giants pay their fair share of taxes. The new rules are set to impact companies like Amazon, Apple, Facebook, and Google. 2. "Germany, France and Italy Sign Pact to Tax Digital Giants" - This article from the New York Times discusses how Germany, France, and Italy have signed a pact to tax digital companies such as Amazon, Apple, Facebook, and Google. The agreement is the first major step in the European Union's effort to tax tech giants. 3. "EU's New Digital Tax Plan: What You Need to Know" - This video from Euronews explains the European Union's new digital tax plan and how it will affect tech giants such as Amazon, Apple, Facebook, and Google. The video also explains the different aspects of the plan and how it will be implemented.
EU exports drop -1.9% yoy in April as shipments to China plunge -15.9% yoy - Action Forex
Eurozone trade data for April showed signs of weakening external demand, with goods exports falling -1.4% yoy to EUR 243.0B, while imports edged up 0.1% yoy to EUR 233.1B. Despite the drop in exports, the region maintained a trade surplus of EUR 9.9B, helped by subdued import growth. Intra-Eurozone trade also declined, down -2.0% yoy to EUR 217.3B.
RetinalGenix Technologies Welcomes Dr. Taimour Langaee as Advisor for DNA GPS Pharmacogenetics Initiatives - ForexTV
Appointment Underscores RetinalGenix’s Commitment to Integrating the Latest Advances in Genomics and Personalized Medicine into its Product PipelineAPOLLO BEACH, Fla., June 13, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), a pioneer in advanced retinal imaging and precision medicine, is pleased to announce the appointment of Dr. Taimour Langaee, MSPH, PhD, as its newest scientific advisor. Dr. Langaee will play a key role in advancing the Company’s DNA GPS Pharmacogenetics initiatives, which are designed to optimize personalized treatment pathways for retinal and systemic diseases through cutting-edge genetic biomarkers and high-resolution retinal imaging. Dr. Langaee will oversee the genotyping/sequencing data processing, genetic and pharmacogenomics data analyses, and clinical genetic association studies between eye diseases and genetic variations. Dr. Langaee brings over two decades of extensive experience in pharmacogenomics/precision medicine, genetics/ epigenetics, genotyping/sequencing, preemptive clinical pharmacogenomics testing and implementation, molecular biology, microbiology/immunology, and infectious disease. He has led and collaborated on major research initiatives throughout his distinguished career, including the NIH Warfarin Study (COAG Trial), the Personalized Medicine Program, and multiple pharmacogenomic studies in cardiovascular, infectious, and neurological diseases. His work has directly influenced the implementation of pharmacogenetics in clinical practice, improving drug safety and efficacy for diverse patient populations. Dr. Langaee currently serves as Professor in the Department of Pharmacotherapeutics and Clinical Research at the University of South Florida’s Taneja College of Pharmacy. He has taught several courses and has mentored and supervised many undergraduate students, PharmD candidates, graduate students, postdoctoral fellows, PGY2 Clinical PGx pharmacy residents, medical residents, and junior faculty members. Prior to this, Dr. Langaee was a leading figure at the University of Florida, where he directed the Center for Pharmacogenomics and Precision Medicine Genotyping Core Laboratory and contributed to numerous NIH-funded projects focused on the genetic determinants of drug response and personalized medicine. Jerry Katzman, MD, CEO of RetinalGenix Technologies, expressed his enthusiasm: “We are thrilled to welcome Dr. Taimour Langaee to our advisory team. His extensive experience in pharmacogenetics and precision medicine will be invaluable as we expand our DNA GPS initiatives. Dr. Langaee’s leadership in translating genetic insights into actionable clinical strategies aligns perfectly with our mission to deliver personalized, data-driven solutions for retinal and systemic health. His expertise will accelerate our efforts to bring the promise of pharmacogenomics to patients and providers worldwide.” Dr. Langaee’s appointment underscores RetinalGenix’s commitment to integrating the latest advances in genomics and personalized medicine into its product pipeline. As the Company continues its efforts to innovate at the intersection of retinal imaging, genetic analysis, and artificial intelligence, Dr. Langaee’s guidance is expected to be instrumental in shaping the future of precision ophthalmology and beyond. The application of RetinalGenix’s technologies goes beyond eye disease prevention. The retina is a window to systemic health, and advanced retinal imaging can reveal early signs of many chronic, pervasive diseases, including but not limited to diabetes, hypertension, cardiovascular disease, neurodegenerative diseases, and chronic kidney disease. RetinalGenix aims to flag early warning signs of these chronic conditions by integrating Pharmacogenetics, high-resolution retinal imaging, remote monitoring, and AI-powered analysis, prompting timely medical evaluation and intervention. This not only helps prevent blindness but also supports better overall health management, reducing the long-term costs associated with chronic disease complications. Timely Intervention and Personalized Care With remote monitoring, changes in retinal health can be identified promptly, enabling healthcare providers to intervene before irreversible vision loss occurs. When integrated with RetinalGenix DNA GPS PharmacogeneticsTM platform, the system intends to further personalize risk assessments and treatment plans based on an individual’s genetic profile. This means that not only are problems detected earlier, but interventions might also be tailored to each patient’s unique risk factors and likely response to treatment, potentially maximizing the effectiveness of preventive strategies. About RetinalGenixRetinalGenix is an ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas by integrating genetic screening, advanced imaging, and therapeutic development. Its proprietary High-Resolution Retinal Imaging and RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular, and metabolic systems, as well as diabetic conditions, Alzheimer’s disease and Parkinson’s disease. RetinalGenix is also developing therapeutic drugs for dry age-related macular degeneration (dry AMD) and Alzheimer’s disease/dementia. Safe Harbor Statement This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements and include statements regarding integrating the latest advances in genomics and personalized medicine into RetinalGenix’s product pipeline, the expected contribution of Dr. Langaee, the Company’s DNA GPS Pharmacogenetics initiatives optimizing personalized treatment pathways for retinal and systemic diseases through cutting-edge genetic biomarkers, and high-resolution retinal imaging, delivering personalized, data-driven solutions for retinal and systemic health, bringing the promise of pharmacogenomics to patients and providers worldwide, innovating at the intersection of retinal imaging, genetic analysis, and artificial intelligence, Dr. Langaee’s guidance being instrumental in shaping the future of precision ophthalmology and beyond, advanced retinal imaging revealing early signs of many chronic, pervasive diseases, including but not limited to diabetes, hypertension, cardiovascular disease, neurodegenerative diseases, and chronic kidney disease, RetinalGenix flagging early warning signs of these chronic conditions by integrating Pharmacogenetics, high-resolution retinal imaging, remote monitoring, and AI-powered analysis, prompting timely medical evaluation and intervention, supporting better overall health management, reducing the long-term costs associated with chronic disease complications, changes in retinal health being identified promptly with remote monitoring, enabling healthcare providers to intervene before irreversible vision loss occurs, the system personalizing risk assessments and treatment plans based on an individual’s genetic profile when integrated with RetinalGenix DNA GPS PharmacogeneticsTM platform, detecting problems earlier, tailoring interventions to each patient’s unique risk factors and likely response to treatment, potentially maximizing the effectiveness of preventive strategies, revolutionizing early disease detection and improving patient outcomes across multiple disease areas by integrating genetic screening, advanced imaging, and therapeutic development, preventing blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular, and metabolic systems, as well as diabetic conditions, developing therapeutic drugs for dry age-related macular degeneration (dry AMD) and Alzheimer’s disease/dementia. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to successfully complete research and further development and commercialization of Company imaging system or drug candidates, the timing, cost and uncertainty of obtaining regulatory approvals for the Company’s imaging system or drug candidates, the Company’s ability to protect its intellectual property, and the risk factors described in the Company’s Annual Report on Form 10-K for the year the risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. For further information, please contact:RetinalGenix Technologies Inc.Media and Investor Relationsir@retinalgenix.com (800) 331-5446
French HICP Shows Decline in May 2025 as Inflationary Pressures Ease - ForexTV
In a significant economic development, France's Harmonized Index of Consumer Prices (HICP) saw a decrease, indicating a slowdown in inflationary pressures. Newly released data as of June 13, 2025, show that the HICP stood at 0.6% in May 2025, a drop from the previous month's rate of 0.9%.This year-over-year comparison demonstrates a deceleration from April 2025's figures, offering a glimpse of relief amid ongoing economic challenges. The French economy, like much of Europe, has been grappling with varying inflationary trends over the past year, and the latest figures suggest a possible stabilization as consumer price growth moderates.Market analysts will be closely watching this trend, considering its implications on both consumer purchasing power and the broader economic policy landscape in France. With the HICP as a key gauge of inflation, the decrease might influence future monetary policy decisions from the European Central Bank.The material has been provided by InstaForex Company - www.instaforex.com
ITM to Provide COMPETE Trial Insights at SNMMI 2025 Annual Meeting in Oral Presentation and Satellite Symposium - ForexTV
Garching / Munich, Germany, June 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide further analysis from its recently completed Phase 3 COMPETE trial in an oral presentation and Satellite Symposium at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, held from June 21 – June 24, 2025 in New Orleans, Louisiana. Details of the Oral PresentationThe data will be presented by Dr. Thomas A. Hope, MD, Chief of Nuclear Medicine at the San Francisco VA Medical Center and Vice Chair of Clinical Operations and Strategy in the Department of Radiology at UCSF in an oral presentation titled, “Predicting the [177Lu]Lu-edotreotide uptake in tumors using pre-therapeutic Ga-68 PET/CT imaging”, on Sunday, June 22 in the Neuroendocrine - Oncology Clinical Diagnosis and Therapy session from 3:30 – 4:45 pm CDT. The presentation will provide an analysis on the 177Lu-edotreotide tumor uptake and its predictability based on pre-therapeutic SSTR PET/CT imaging and other factors. Symposium DetailsThe symposium, “Pursuing the Art and Science of RPT: COMPETE Results and the Evolution of Dosimetry,” will take place on Sunday June 22, from 6:30 pm – 7:30 pm CDT. The symposium will feature an overview of the GEP-NET treatment landscape, including findings from the Phase 3 COMPETE trial, and perspectives on dosimetry standardization today and in the future. COMPETE evaluated n.c.a 177Lu-edotreotide (also known as ITM-11) in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NET) and ITM announced the positive Phase 3 results in March 2025. Date and Time: Sunday, June 22, from 6:30 pm – 7:30 pm CDTLocation: Ernest N. Morial Convention Center, New Orleans, LA; Room R04-R05Speakers and Topics: GEP-NET treatment landscape, COMPETE trial results, and COMPOSE trial designJonathan Strosberg, MD; Section Head, Neuroendocrine Division Program Chair, Gastrointestinal Department Oncology Research Program Moffitt Cancer CenterCOMPETE dosimetry sub-study and the evolution of dosimetryJohn Sunderland, PhD; Professor of Radiology Nuclear Medicine Division University of Iowa Dr. Celine Wilke Participates in Entrepreneur’s PanelAs part of the SNMMI conference, Dr. Celine Wilke, ITM’s Chief Medical Officer will participate in the “Entrepreneur’s Panel: Community Based Sites – Accelerating Clinical Trials and Expanding Access,” on Saturday, June 21, from 3:30 – 4:45 pm CDT.ITM will further be present at the conference with a booth (booth number: 1001) providing information on the company’s latest innovations in radiopharmaceutical therapy (RPT), its pipeline of RPT therapeutics and the company’s capabilities to produce high-quality medical radioisotopes for global partners and its own pipeline. About the COMPETE TrialThe COMPETE trial evaluated 177Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic agent compared to everolimus, a targeted molecular therapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This trial met its primary endpoint, with 177Lu-edotreotide demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus. 177Lu-edotreotide is also being evaluated in COMPOSE, a Phase 3 study in patients with well-differentiated, aggressive Grade 2 or Grade 3, SSTR-positive GEP-NET tumors. About ITM Isotope Technologies Munich SEITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com ITM ContactCorporate CommunicationsKathleen Noonan/Julia WestermeirPhone: +49 89 329 8986 1500Email: communications@itm-radiopharma.com Investor RelationsBen OrzelekPhone: +49 89 329 8986 1009Email: investors@itm-radiopharma.com Attachment 20250613_ITM to Provide COMPETE Trial Insights at SNMMI 2025 Annual Meeting in Oral Presentation and Satellite Symposium
European Currencies Hit Yearly Highs | Market Pulse
European currencies, particularly EUR/USD and EUR/JPY, are showing strong gains amid a notable weakening of the US dollar. Pressure on the greenback intensified following the release of a series of disappointing macroeconomic indicators. In May, the core Consumer Price Index (CPI) rose by just 0.1% — well below
FTSE 100 falls on Middle East tensions - UK Investor Magazine
The FTSE 100 slipped on Friday after Israel launched an attack on Iran’s nuclear facilities and Iran responded with a drone attack. Oil prices soared and stocks sank in the immediate reaction. Risk aversion spread through markets sending European equities sharply lower. “‘Israel strikes Iranian nuclear facilities’ is always a shocking headline to read, so […]